Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.

Authors:
Laura Campora
Laura Campora
From Westmead Institute for Medical Research
Mohamed El Idrissi
Mohamed El Idrissi
Service de Chirurgie Osteo-Articulaire B4
Lidia Oostvogels
Lidia Oostvogels
Health Sciences North and Advanced Medical Research Institute of Canada
Canada
Thomas C Heineman
Thomas C Heineman
Saint Louis University School of Medicine
United States

Vaccine 2019 Apr 29;37(18):2482-2493. Epub 2019 Mar 29.

GSK, Wavre, Belgium. Electronic address:

Background: The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.

Methods: Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30 days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12 months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.

Results: Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.

Conclusions: No safety concerns arose, supporting the favorable benefit-risk profile of RZV.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2019.03.043DOI Listing
April 2019
4 Reads

Publication Analysis

Top Keywords

rzv placebo
16
rzv
10
recombinant zoster
8
zoster vaccine
8
placebo
8
placebo recipients
8
adjuvanted recombinant
8
fatal aes
8
safety
6
aes
5
14660 placebo
4
evaluated 14645
4
study periodresults
4
periodresults safety
4
safety evaluated
4
14645 rzv
4
rzv 14660
4
unsolicited aes
4
driven transient
4
difference driven
4

Similar Publications